

Edgar Filing: MusclePharm Corp - Form NT 10-K

MusclePharm Corp  
Form NT 10-K  
April 01, 2019

OMB APPROVAL  
OMB Number: 3235-0058  
Expires: February 28, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Estimated average burden  
hours per response.....2.50

FORM 12b-25 SEC FILE NUMBER

CUSIP NUMBER

NOTIFICATION OF LATE FILING

(Check one):            Form 10-K            Form 20-F            Form 11-K            Form 10-Q            Form 10-D

For Period Ended: December 31, 2018

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

MusclePharm Corporation  
Full Name of Registrant

N/A  
Former Name if Applicable

4400 Vanowen St.  
Address of Principal  
Executive Office (Street  
and Number)

Burbank, CA 91505  
City, State and Zip Code



PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

(Attach extra Sheets if Needed)

As previously disclosed in a Form 8-K filed on March 14, 2019, during the preparation of its 2018 annual consolidated financial statements, the Company determined that the systems, processes and controls related to sales cut off were not sufficient to accurately record revenue in the correct reporting period. This resulted in errors in the Company's unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2018. The Company is in the process of restating its unaudited condensed consolidated financial statements for the foregoing periods and will file an amended Form 10-Q for the quarter ended September 30, 2018. The Company will not be able to file its Form 10-K for the year ended December 31, 2018 until after the filing of the amended Form 10-Q.

PART IV — OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

Ryan Drexler (800) 292-3909  
(Name) (Area Code) (Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company

Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes

No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes

No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.



MusclePharm Corporation  
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto  
duly authorized.

Date: April 1, 2019

By: /s/ Ryan Drexler  
Name: Ryan Drexler  
Title: Chief Executive Officer